Editor’s Note: Today’s post comes from contributing editor Bob Beach. Beach is a Ph.D. candidate in history at the University of Albany, SUNY.
It almost seems, given the existence of much more pressing matters, that a Points election preview is not even worth our time. As a personal matter, I’ll take that stance explicitly at the end of all of this. But as a drug historian, writing to folks interested in drug policies, such matters are always worth some of our time. Let’s take a quick break from Trump’s COVID diagnosis, two recent debates and a cancelled third, and ongoing conflict over Trump’s SCOTUS nomination, and review some of the key drug policy issues that will figure into the 2020 election season.